论文部分内容阅读
目的评估单用重组人生长激素(rhGH)或联合促性腺激素释放激素类似物(GnRHa)治疗青春早期特发性矮小(ISS)和生长激素缺乏症(GHD)患儿的疗效。方法 ISS患儿41例,13例单独用rhGH治疗,28例联合应用rhGH和GnRHa治疗;另选择GHD患儿21例,12例单独用rhGH治疗,9例联合用rhGH和GnRHa治疗。观察治疗2年后患儿身高、骨龄、预测终身高(PAH)及近似终身高(NFH)。结果 ISS及GHD患儿,单用rhGH或rhGH联合GnRHa治疗后,患儿身高均较治疗前显著增加(P<0.05),但组间比较并无统计学差异(P>0.05)。结论单用rhGH或rhGH联合GnRHa治疗青春早期ISS和GHD均能明显增加患儿身高;但与单用rhGH比较,rhGH联合GnRHa治疗并无明显优势。
Objectives To evaluate the efficacy of rhGH alone or in combination with GnRHa in the treatment of children with idiopathic idiopathic short stature (ISS) and growth hormone deficiency (GHD) in adolescence. Methods Thirty-one children with ISS were enrolled. Thirteen patients were treated with rhGH alone and 28 patients combined with rhGH and GnRHa. Another 21 patients with GHD were selected, 12 patients were treated with rhGH alone and 9 patients were treated with rhGH and GnRHa. The height, skeletal age, predicted height at rest (PAH) and approximate end-of-life height (NFH) were observed 2 years after treatment. Results After treatment with rhGH or rhGH combined with GnRHa, the height of children with ISS and GHD increased significantly (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion Treatment of early ISS and GHD with rhGH alone or rhGH combined with GnRHa significantly increased the height of children. However, rhGH combined with GnRHa had no obvious advantage compared with rhGH alone.